http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Estimated incidence of juvenile-onset recurrent respiratory papillomatosis in Korea
Jin-Kyoung Oh,Hwa Young Choi,Minji Han1,Yuh-Seog Jung,Sang Joon Lee,Moran Ki 한국역학회 2021 Epidemiology and Health Vol.43 No.-
OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is caused by human papillomavirus (HPV) types 6 and 11 and is potentially preventable through vaccination. This study estimated the incidence of juvenile-onset RRP before the implementation of the national HPV vaccination program in Korea. METHODS: We conducted a cohort study using claims data provided by a mandatory insurance program to estimate the incidence of RRP and associated healthcare use. Patients with juvenile RRP were defined as those aged ≤12 years with ≥2 admissions or ≥2 outpatient visits during which they received the International Classification of Diseases, 10th revision code for benign neoplasms of the larynx (D14.1). RESULTS: During 2002-2014, 123 children (74 boys and 49 girls) were diagnosed with RRP. The patients had a mean of 6.5 person-years of follow-up. The incidence was estimated at 0.30/100,000 person-years. The median age at diagnosis was 4.0 years (mean, 4.3). Thirty-six (29.3%) patients underwent surgery, including 23 patients (18.7%) who underwent 2 or more surgical procedures. Severe disease, measured by more frequent surgical procedures and shorter time intervals between consecutive operations, was associated with a younger age at diagnosis. CONCLUSIONS: The estimated incidence of juvenile-onset RRP in Korea was similar to that reported in other countries. The RRP burden should continue to be monitored using National Health Insurance Service claims data.
Seismic reflection imaging of Quaternary faulting offshore the southeastern Korean Peninsula
Han-Joon Kim,YoungSook Baek,Hyeong-Tae Jou,Sang Hoon Lee,Seonghoon Moon,Jin Soo Kim,Su-hwan Lee,Gwang Hoon Lee,Seung-Goo Kang,Woo-Hyun Son,Ryeongsim Seok 한국지질과학협의회 2016 Geosciences Journal Vol.20 No.3
The Yangsan Fault System (YFS) is a dominating tectonic structure in the southeastern part of the Korean Peninsula. The YFS consists of NNE-striking dextral strike-slip faults that are traced to the southeastern coast of the Korean Peninsula. We acquired high-resolution seismic profiles offshore the southeastern Korean Peninsula to investigate how the YFS extends offshore and constrain the age of fault activity using stratigraphic interpretation. The seismic profiles image near-vertical faults trending NE to NNE that constitute a fault zone similar to a duplex structure at a releasing bend of a right-lateral strike-slip fault. The faults are interpreted as an offshore extension of the Ilgwang fault that is a member of the YFS. Stratigraphic interpretation of seismic profiles indicates that the offshore faults were activated repeatedly in the Pliocene and Quaternary. The right-lateral activity of the Ilgwang fault is consistent with the current stress regime in and around the southeastern Korean Peninsula that dictates the P-axis direction in the E-W or ENE-WSW since the Pliocene.
DESIGN AND FABRICATION OF THE MICRO-GRIPPER FOR MANIPULATING THE CELL
Han, Kyungnam,Lee, Sang Hoon,Moon, Wonkyu,Park, Joon-Shik,Moon, Chan-Woo Taylor Francis 2007 Integrated ferroelectrics Vol.89 No.1
<P> A novel micro-gripper is designed and fabricated to manipulate the micro-sized object like a cell. In order to grip the cell, the micro-gripper should be operated in the liquid environment. Since the mechanical type micro-gripper is rarely affected by the surroundings, it is suitable to treat the cell. The other consideration for manipulating the cell is properties of the cell such as the bursting force and the maximum deformation of the cell for the applied force. Thus, the sensor system is needed to measure the force on the cell during the gripping. On this micro-gripper, a piezoresistive sensor is integrated for sensing the gripping force. Using the fabricated micro-gripper, micro-glass beads are successfully manipulated in the water. The resistance in the piezoresistor is changed by 0.06∼ 0.07% for each 10 μ N of the applied force. Therefore, since the proposed micro-gripper satisfies the requisite conditions, it can be utilized for manipulation of the cell.</P>
( Sang Jun Suh ),( Hyung Joon Yim ),( Young-sun Lee ),( Han Ah Lee ),( Tae Hyung Kim ),( Sun Young Yim ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Various models for the prediction of hepatocellular carcinoma (HCC) in the patients with chronic hepatitis B (CHB) were suggested. The aim of study is to identify if the HCC risk scores are improved as antiviral therapy is prolonged in the patients with CHB-related liver cirrhosis. Methods: The patients with CHB who received entecavir (ETV) or tenofovir (TDF) were investigated retrospectively. Patients with liver cirrhosis patients diagnosed by sonography, CT or biopsy were enrolled. We calculated the HCC risk scores at pre-antiviral therapy, and each year from year 1 to 5 of post-antiviral therapy. The models were GAG-HCC, CU-HCC, REACH-B, modified REACH-B (mREACH-B), LSM-HCC, and PAGE-B. The primary endpoint was decrease of the risk scores after antiviral therapy. The secondary endpoint was finding the best model by AUROC after antiviral therapy. Results: A total of 362 patients were enrolled, and 198 and 164 patients were treated by ETV and TDF respectively. Child- Pugh scores were 5.7±1.3 and MELD were 9.9±3.8. Fifty six patient (15.5 %) occurred HCC at median 1.6 years (0.1-9.7 years). Most HCC scores (GAG, CU-HCC, REACH-B) decreased at year 1 and plateaued from year 1 to 5. mREACH-B and LSM-HCC scores decreased until year 2 and plateaued after year 2. PAGE-B showed no decrease from pre to post-antiviral therapy. The AUROC of PAGE-B was largest at baseline (GAG-HCC 0.472, CU-HCC 0.753, REACH-B 0.633, mREACH-B 0.688, LSM-HCC 0.649, and PAGE-B 0.760). After antiviral therapy, the AUROC changed. AUROCs of models employing HBV DNA levels increased (GAG-HCC, REACH-B, and LSM-HCC), that of liver stiffness based models (mREACH-B and PAGE-B) were persistent, and that of models employing hepatic function (CU-HCC) decreased (GAG-HCC 0.582, CU-HCC 0.686, REACH-B 0.689, mREACH-B 0.689, LSM-HCC 0.716, and PAGE-B 0.755 at 1year). The decrease of scores from baseline to each years were not different between ETV and TDF (all P>0.05). AUROC were largest in PAGE-B, however the scores were not changed after antiviral therapy. Second largest AUROC is that of LSM-HCC at year 1 and its AUROC became larger after antiviral therapy Conclusions: In conclusion, HCC prediction models such as PAGE-B and LSM-based models worked well in patients with HBV-related cirrhosis and decrease of the scores was associated with effects of the antiviral therapy.
Altered gene expression of caspase-10, death receptor-3 and IGFBP-3 in preeclamptic placentas /
Han, Jae Yoon,Kim, Yoon Sook,Cho, Gyeong Jae,Roh, Gu Seob,Kim, Hyun Joon,Choi, Won Jun,Paik, Won Young,Rho, Gyu Jin,Kang, Sang Soo,Choi, Wan Sung Korean Society for Molecular and Cellular Biology 2006 Molecules and cells Vol.22 No.2
( Han Ah Lee ),( Yoo Ra Lee ),( Tae Hyung Kim ),( Sun Young Yim ),( Young-sun Lee ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Dong-sik Kim ),( Hyung Joon Yim ),( Jong Eun 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: This study compared the survival benefits between surgical resection and radiofrequency ablation (RFA) in single small hepatocellular carcinoma (HCC). Methods: Patients registered in the database of Korea central cancer registry for HCC between 2008 and 2014 who received surgical resection or RFA for a single HCC of maximum size 3cm were reviewed. The cumulative overall survival (OS) and retreatment-free survival (RFS) were compared according to the type of treatment. Results: A total of 1426 patients were included, 662 (46.4%) in the resection group and 764 (53.6%) in the RFA group. The 5-year OS rates were 91.8% for resection, and 84.9% for RFA, respectively (P<0.001). The 5-year RFS rates were 77.8% for the resection and 70.5% for RFA, respectively (P=0.002). In patients with maximum tumor size <2cm, there was no significant difference in 5-year OS rates between the two groups (91.8% for resection, and 87.5% for RFA, respectively; P=0.094), while resection was superior to RFA in the 5-year RFS rates (81.0% for resection, and 72.3% for RFA, respectively; P=0.017). Resection was superior in both 5-year OS and RFS rates in those with maximum tumor size ≥2cm and <3cm (91.9% for resection, and 80.2% for RFA, respectively; P<0.001; 76.2% for resection, and 67.2% for RFA, respectively; P=0.007). In the entire cohort, type of treatment (HR 1.457, P=0.032), age (HR 1.031, P<0.001), serum albumin (HR 0.466, P<0.001), and serum creatinine level (HR 1.282, P<0.001) were independently associated with survival. Type of treatment (HR 1.544, P<0.001) and maximum size of tumor (HR 1.353, P=0.002) were independent predictors of RFS. Conclusions: In patients with maximum tumor size <2cm, OS is comparable between resection and RFA groups, while RFS is better in resection group. Surgical resection is superior in both OS and RFS in patients with maximum tumor size ≥2cm and <3cm.
( Han Ah Lee ),( Seung Up Kim ),( Hyung Joon Yim ),( Yeon Seok Seo ),( Young-sun Lee ),( Sang Jun Suh ),( Ki Tae Suk ),( Soung Won Jeong ),( Young Kul Jung ),( Moon Young Kim ),( Ji Hoon Kim ),( Sang 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The Baveno VI consensus recommended that screening endoscopy can be safely avoided in patients with a liver stiffness (LS) < 20 kPa and platelet count >150x10<sup>9</sup>/L. Also, the Expanded Baveno VI criteria was proposed to spare more endoscopies. We aimed to validate and revise these criteria with other non-invasive markers in ruling out high-risk varices. Methods: Patients with compensated advanced chronic liver disease (cACLD), which is defined as LS ≥10 kPa, and who had endoscopy within 6 months of the transient elastography in 8 centers were included. Patients with hepatocellular carcinoma and those with Child-Pugh score >6 was excluded. Varices needing treatment (VNT) were defined as ≥F2 varices or varices with red color sign. Results: A total of 1218 patients with cACLD were included. Age was 56.0±11.5 years and 778 patients (63.9%) were men. Chronic hepatitis B was the most frequent underlying liver disease (479 patients, 39.3%), followed by alcoholic liver disease (359 patients, 29.5%). VNT were noted in 249 patients (20.4%). With Baveno VI criteria, VNT loss rate was only 1.9%, while sparing endoscopy rate was only 25.7%. With the Expanded Baveno VI criteria, 43.5% of endoscopies were avoided, but VNT loss rate was 5.8%. We explored various other parameters and cutoff values in ruling out VNT. Platelet >110x109/L and LS <20 kPa spared 39.1% of endoscopy with 4.4% of low VNT loss rate. When the LS-spleen diameter to platelet ratio score (LSPS) was applied, LSPS < 14.5 could spare more endoscopies (44.2%) with low VNT loss rate (4.5%). Conclusions: Combination of platelet >110x10<sup>9</sup>/L and LS <20 kPa has VNT loss rate less than 5%, and high endoscopic sparing rate in patients with cACLD. This study also showed LSPS <14.5 as a better strategy with increased number of spared endoscopies while maintaining excellent VNT loss rate.
( Sang Jun Suh ),( Hyung Joon Yim ),( Ji Hye Seo ),( Han Ah Lee ),( Tae Hyung Kim ),( Young Sun Lee ),( Jong Jin Hyun ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Jong Eun Yeon ),( Kwan So 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, the influence of sorafenib on the replication of HBV remains unknown. Herein, we evaluated the rate of HBV reactivation during sorafenib therapy in chronic hepatitis B (CHB) patients with advanced HCC. Methods: Four hundreds thirty five advanced HCC patients who visited three hospitals affiliated with Korea University from January 2004 to December 2012 were retrospectively reviewed. Among them, 327 patients were HBsAg positive. Two hundred sixty four received antiviral therapy before initiation of sorafenib therapy, and 64 patients were treatment naive with regard to anti-HBV therapy. Patients who received sorafenib less than 4 weeks, those who had not follow-up HBV DNA value, and patients who received other treatment than sorafenib were excluded. Finally, 133 and 28 patients were analyzed, respectively in each group. HBV reactivation were defined as increase of HBV DNA >10 times of baselines or ≥ 2000 IU/mL in patients with baselines HBV DNA < 2000 IU/mL. We further investigated reactivation rates in propensity score matched liver cirrhosis patients without HCC. Results: Mean age was 54.87±9.34 and 83.2% were male. All patients were Barcelona Clinic of Liver Cancer Stage C and the sum of tumor diameter was 10.42±5.78 cm. Mean baseline HBV DNA level was 2.84±1.60 log IU/mL. Median survival was 5.97 months. At 12, 24, and 48 weeks of the sorafenib therapy, HBV reactivation occurred in 5.26%, 12.0%, 14.3% of antiviral therapy group while it developed in 28.6%, 39.3%, and 42.9% of HBV therapy naïve group, respectively. The reactivation rates was significantly higher in patient who didn’t received antiviral therapy (p = 0.001). The antiviral therapy (HR 0.250, C.I. 0.104-0.604, p = 0.002) was independent factor related to HBV reactivation by logistic regression analysis. When the 28 HBV therapy naive HCC patients who received sorafenib were compared with propensity score matched 84 HBV therapy naïve liver cirrhosis patients without HCC, the cumulative reactivation rates were also significantly higher in the former group by log-rank test (p <0.001). Conclusions: The risk of HBV reactivation is high in CHB patients receiving sorafenib due to advanced HCC. It would be necessary to administer pre-emptive antiviral therapy before sorafenib initiation.